Home » Stocks » Frequency Therapeutics

Frequency Therapeutics, Inc. (FREQ)

Stock Price: $22.32 USD 0.35 (1.59%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 750.98M
Revenue (ttm) 44.73M
Net Income (ttm) -17.01M
Shares Out 33.65M
EPS (ttm) -10.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $22.32
Previous Close $21.97
Change ($) 0.35
Change (%) 1.59%
Day's Open 21.64
Day's Range 21.13 - 22.53
Day's Volume 145,524
52-Week Range 13.60 - 28.78

More Stats

Market Cap 750.98M
Enterprise Value 556.13M
Earnings Date (est) Nov 23, 2020
Ex-Dividend Date n/a
Shares Outstanding 33.65M
Float 28.77M
EPS (basic) 3.80
EPS (diluted) -10.29
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.21M
Short Ratio 18.94
Short % of Float 14.62%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 16.79
PB Ratio 4.56
Revenue 44.73M
Operating Income -19.60M
Net Income -17.01M
Free Cash Flow n/a
Net Cash 194.85M
Net Cash / Share 5.79
Gross Margin 28.94%
Operating Margin -43.80%
Profit Margin -40.40%
FCF Margin n/a
ROA -10.22%
ROE -17.75%
ROIC 55.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(44.85% upside)
Current: $22.32
Target: 32.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit28.95--
Operating Income-20.68-18.94-16.31
Net Income-18.75-19.17-20.24
Shares Outstanding8.651.530.70
Earnings Per Share-2.29-12.53-28.79
Operating Cash Flow34.22-17.02-14.61
Capital Expenditures-1.06-0.44-1.86
Free Cash Flow33.15-17.46-16.48
Cash & Equivalents21742.1917.94
Net Cash / Debt21742.1917.94
Book Value167-52.06-29.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Frequency Therapeutics, Inc.
Country United States
Employees 43
CEO David L. Lucchino

Stock Information

Ticker Symbol FREQ
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FREQ
IPO Date October 3, 2019


Frequency Therapeutics, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.